What is HaystackMRD?
Founded in 2021 and headquartered in Baltimore, Maryland, Haystack Oncology is a cancer treatment and therapy monitoring company. The company is focused on advancing cancer care through innovative technological solutions, aiming to provide more effective and personalized treatment strategies for patients. Its work in therapy monitoring suggests a commitment to precision medicine and data-driven healthcare.
How much funding has HaystackMRD raised?
HaystackMRD has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from Exact Ventures, Bruker, Catalio Capital Management, and Alexandria Venture Investments
Key Investors in HaystackMRD
Exact Ventures
Exact Ventures is an independent market intelligence firm specializing in telecommunications and networking technologies, providing in-depth market research and advisory services.
Bruker
Bruker Corporation is a global leader in scientific instrumentation, analytical technologies, and diagnostic solutions, serving customers across research, industry, and government.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets.
What's next for HaystackMRD?
The substantial enterprise-level funding indicates HaystackMRD is likely in a scaling phase, moving beyond initial development to expand its market reach and further refine its therapeutic offerings. This strategic investment will likely fuel research and development, clinical trials, and the commercialization of its cancer treatment and monitoring technologies. The company's focus on precision medicine and therapy monitoring aligns with current trends in oncology, suggesting a strong potential for future impact and innovation in the fight against cancer.
See full HaystackMRD company page
